PRİMER VAJİNAL KANSERDE VAJİNAL SU-BAZLI JEL YARDIMLI MANYETİK REZONANS GÖRÜNTÜLEME
İki vajinal squamoz hücreli karsinom olgusunun, vajene su-bazlı jel doldurularak alınan manyetik rezonans görüntülemelerinin, genel
anestezi altında yapılan fizik muayene bulgularına yapabileceği ek katkıları değerlendirdik. Sunduğumuz iki olgu da genel anestezi altında
yapılan fizik muayeneye göre evre 1 olarak değerlendirildi. Ardından her iki hastaya da vajene su-bazlı jel ile doldurup vajen duvarlarının
kollapsını engelleyen, bu sayede vajendeki tümör anatomisini ve yayılımını daha iyi gösteren bir teknikle manyetik rezonans
görüntüleme(MRG) yapıldı. Olgulardan birinin MRG bulgularında subvajinal dokulara infiltrasyon izlendi. Bu nedenle bu hastada cerrahi
tedaviden vazgeçtik ve primer kemoradyasyon ile tedaviye karar verdik. Vajinal su-bazlı jel ile yapılan pelvik MRG’nin vajinal kanser
olgularında tümör anatomisini ve paravajinal dokulara infiltrasyonu göstermede genel anestezi altında yapılan fizik muayeneye üstün
olduğuna ve bu nadir jinelkolojik kanserlerin daha ideal yönetimine katkı sağlayacağına inanmaktayız.
MAGNETIC RESONANCE IMAGING GUIDES THE MANAGEMENT OF PRIMARY VAGINAL CANCER
We report two cases of vaginal squamoz cell carcinoma with magnetic resonance imaging findings. Both of the patients were staged as
stage 1 with physical examination findings under general anesthesia. We performed magnetic resonance imaging for these patients filling
water-based gel to their vagina during the scan for preventing collapse of vaginal walls so that we could reveal the tumor anatomy and
extension more accurately. One of the patients MRI findings showed an infiltration through subvaginal tissues. So we abandoned surgical
treatment for this patient and choose radiotherapy. We think that, pelvic MRI performed with vaginal water-based gel can demonstrate
tumor infiltration to paravaginal tissues better than physical examination, which helps well-directed management of this rare gynecological
cancer
___
- 1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA
Cancer J Clin 2014;64:9
- 2. Daling JR, Madeleine MM, Schwartz SM, et al. A
population-based study of squamous cell vaginal cancer:
HPV and cofactors. Gynecol Oncol 2002;84:263e70.
- 3. Frank SJ, Deavers MT, Jhingran A, Bodurka DC, Eifel PJ.
Primary adenocarcinoma of the vagina not associated
with diethylstilbestrol (DES) exposure. Gynecol Oncol
2007;105:470
- 4. Lilic V, Lilic G, Filipovic S, Visnjic M, Zivadinovic R.
Primary carcinoma of the vagina. J BUON 2010;15:241–7.
- 5. Hacker NF, Eifel PJ, van der Velden J. Cancer of the
vagina. Int J Gynaecol Obstet 2012;119(Suppl. 2):S97–9.
- 6. Miner TJ, Delgado R, Zeisler J, et al. Primary vaginal
melanoma: a critical analysis of therapy. Ann Surg Oncol
2004;11:34–9.
- 7. Kirschner AN, Kidd EA, Dewees T, Perkins SM.
Treatment approach and outcomes of vaginal melanoma.
Int J Gynecol Cancer 2013;23:1484–9.
- 8. Beller U, Benedet JL, Creasman WT, et al. Carcinoma
of the vagina. FIGO 26th annual report on the results of
treatment in gynecological cancer. Int J Gynaecol Obstet
2006;95(Suppl. 1):S29–42.
9. Hacker NF, Eifel PJ, van der Velden J. Cancer of the
vagina. Int J Gynecol Obstet 2012;119(Suppl. 2):S97e9
- 10. Madsen BS, Jensen HL, van den Brule AJ, et al. Risk
factors for invasive squamous cell carcinoma of the
vulva and vaginaepopulation-based case-control study in
Denmark. Int J Cancer 2008;122:2827e34.
- 11. Liao JB, Jean S, Wilkinson-Ryan I, et al. Vaginal
intraepithelial neoplasia (VAIN) aft er radiation therapy
for gynecologic malignancies: a clinically recalcitrant
entity. Gynecol Oncol 2011;120(1):108e12.
- 12. Current FIGO staging for cancer of the vagina, fallopian
tube, ovary, and gestational trophoblastic neoplasia. Int J
Gynaecol Obstet 2009;105(1):3e4.
- 13. Rajaram S, Maheshwari A, Srivastava A Staging for
vaginal cancer Best Practice & Research Clinical
Obstetrics and Gynaecology 29 (2015) 822e832
- 14. Bipat S, Glas AS, van der Velden J, et al. Computed
tomography and magnetic resonance imaging in staging
of uterine cervical carcinoma: a systematic review.
Gynecol Oncol 2003;91(1):59e66.
- 15. Hricak H, Gatsonis C, Chi DS, et al. Role of imaging in
pretreatment evaluation of early invasive cervical cancer:
results of the intergroup study American
- 16. Taylor MB, Dugar N, Davidson SE, et al. Magnetic
resonance imaging of primary vaginal carcinoma. Clin
Radiol 2007; 62(6):549e55.
- 17. Lee LJ, Jhingran A, Kidd E, et al. ACR appropriateness
criteria® management of vaginal cancer. Oncology
2013 [accessed 28.10.14], http://www.cancernetwork.
com/oncology-journal/acr-appropriateness-criteriamanagement-vaginal-cancer/accessed.
- 18. Griffi n N, Grant LA, Sala E. Magnetic resonance
imaging of vaginal and vulval pathology. Eur Radiol
2008;18:1269e80
- 19. Chang YC, Hricak H, Th urnher S. Lacey CG vagina:
evaluation with MR imaging. Part II. Neoplasms.
Radiology 1988;169: 175e9.
- 20. Young P, Daniel B, Sommer G, Kim B, Herfk ens R
Intravaginal Gel for Staging of Female Pelvic Cancers
Preliminary Report of Safety, Distention, and Gel-Mucosal
Contrast During Magnetic Resonance Examination.
Comput Assist Tomogr & Volume 36, Number 2, March/
April 2012
- 21. Atcı N, Özgür T, Öztürk F, Dolapçıoğlu KS Utility of
intravaginal ultrasound gel for local staging of cervical
carcinoma on MRI. Clinical Imaging 40 (2016) 1104-
1107